LIST OF CLINICAL TRIALS THAT ARE CURRENTLY RECRUITING PARTICIPANTS

Updated as of August 6, 2018

For studies that are active but not recruiting participants, please contact the Clinical Research Center. This list does not include studies under the Cellular Therapeutics Center.
 

Active Cutaneous Lupus Erythematosus
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations  and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

Principal Investigator:   Dr. Jose Paulo Lorenzo
Co-Investigator:              Dr. Andrei Rhoneil Rodriguez

Learn More


Chronic Hepatitis B
A Double-blind, Placebo-controlled study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

Principal Investigator:   Dr. Madalinee Eternity Labio
Co-Investigator:              Dr. Ernesto Olympia

Learn More


Conjunctivitis
A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral/Bacterial Conjunctivitis

Principal Investigator:   Dr. Edward Uy

Learn More
 


Diabetes Mellitus 
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes

Principal Investigator:    Dr. Sylvia Capistrano-Estrada


Learn More


Liver Cancer
Phase 1 Dose Escalation Trial to evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Reximmune-C2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes) in Refractory patients with primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver

Principal Investigator:   Dr. Ma. Belen M. Tamayo
Co-Investigator:              Dr. Regina Edusma-Dy
 

Lung Cancer
Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care

Principal Investigator:   Dr. Ma. Belen M. Tamayo
Co-Investigator:              Dr. Regina Edusma-Dy

Learn More

A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator:   Dr. Ma. Belen M. Tamayo

Learn More

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable, Non-small Cell Lung Cancer (Stage III)

Principal Investigator:   Dr. Barbara Domingo

Learn More


Neurogenic Detrusor Overactivity
A 24-Week Randomized, Open-Label, Study to Evaluate The Safety And Efficacy Of Fesoterodine in Subjects Aged 6 to 17 Years with Symptoms of Detrusor Overactivity Associated with a Neurological Condition (Neurogenic Detrusor Overactivity)

Principal Investigator:   Dr. Jose Dante Dator
Co-Investigator:              Dr. Carlos Ramon Torres

Learn More


Pulmonary Arterial Hypertension
A Multicenter, Open-Label, Randomized, Event-Driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan versus Standard of Care in Children with Pulmonary Arterial Hypertension.

Principal Investigator:   Dr. Aurelia Leus
Co-Investigator:              Dr. Rozaida Villon

Learn More